One World Cannabis to Present at the Wall St. Conference in Miami on March 23rd

PETACH TIKVA, Israel, March 19, 2015 /PRNewswire/ --

OWC Pharmaceutical Research Corp. (OTCQB: OWCP), an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, today announced that its wholly owned subsidiary One World Cannabis Ltd. ("the Company") will present at the, invitation only, WALL ST. Conference ("WSC") in Miami, Florida on March 23rd 2015 at the Biltmore Hotel to elite Wall Street professionals.

     (Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )
     (Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )

Mr. Ziv Turner, the Company's Chief Executive Officer will provide a high-level overview of the Company. Dr. Alan Shackelford, the Company's Chief Science Officer was invited to be a keynote speaker, and will be discussing the company's innovative approach to using cannabinoid-based therapies to treat Multiple Myeloma and other indications.

The WALL ST. Conference ("WSC") is the premiere conference in the micro-cap arena and venture capital. The most senior and elite Wall Street professionals attend this conference. Industry leaders from the hedge fund, investment banking, and private equity worlds, as well as sophisticated investors, all attend the WALL ST. Conference every year to discuss significant trends in the industry.

The WSC is organized by Mr. Jason S. Lyons, Founder & CEO.

"We are excited to be presenting to such high profile and experienced professionals with the deep vision of the future of Medical Cannabis," said One World Cannabis CEO Ziv Turner.  "I am absolutely sure that our business structure, activities, focus on new medical cannabis products and international regulation will be most appealing to such professionals."

About One World Cannabis Ltd. 

One World Cannabis Ltd. ("the Company") is an Israel-based company founded in 2014 by a group of professionals with expertise in the field of medical cannabis (marijuana) treatment and medical cannabis regulatory affairs. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTCQB: OWCP).

Notice Regarding Forward-Looking Statements 

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact:
Ziv Turner, CEO
One World Cannabis Ltd. (OWC)
Tel: +972(0)54-5500450
Email: [email protected]

SOURCE OWC Pharmaceutical Research Corp.